Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Share-based Compensation came in at $779000.0 in Q1 2026, up 109.05% on a QoQ basis from -$8.6 million in Q4 2025.
Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Share-based Compensation data on file, last reported at $779000.0 in Q1 2026.
- Quarterly Share-based Compensation changed N/A year-over-year to $779000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 304.93% YoY) and the FY2025 annual result came in at $510000.0, changed N/A from the prior year.
- Share-based Compensation advanced to $779000.0 in Q1 2026, from -$8.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.6 million in Q3 2025 to a low of -$8.6 million in Q4 2025.
- A 5-year average of $880000.0 and a median of $777500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 266.85% — and 2024, when it sank 170.44%.
- Tracing AVTX's Share-based Compensation over 5 years: stood at $843000.0 in 2022, then decreased by 7.95% to $776000.0 in 2023, then plunged by 181.06% to -$629000.0 in 2024, then sank by 1267.73% to -$8.6 million in 2025, then jumped by 109.05% to $779000.0 in 2026.
- The last three Share-based Compensation figures came in at $779000.0 (Q1 2026), -$8.6 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 5.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Mn |
| Jun 30, 2026 | 5.31 Mn |
| Mar 31, 2026 | 779,000.00 |
| Mar 31, 2026 | 779,000.00 |
| Dec 31, 2025 | -8.60 Mn |
| Dec 31, 2025 | -8.60 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Jun 30, 2025 | 509,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Jun 30, 2024 | -629,000.00 |
| Jun 30, 2024 | -629,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | 776,000.00 |
| Dec 31, 2023 | 776,000.00 |
| Sep 30, 2023 | 953,000.00 |
| Sep 30, 2023 | 953,000.00 |
| Jun 30, 2023 | 893,000.00 |
| Jun 30, 2023 | 893,000.00 |